Health Canada approves REBINYN® (Coagulation Factor IX (Recombinant), pegylated) for the treatment of routine prophylaxis to prevent or reduce frequency of bleeding episodes in children with hemophilia B

/CNW/ - Novo Nordisk announced today that Health Canada has approved a new indication for REBINYN® (Coagulation Factor IX (Recombinant), pegylated) for the...

Related Keywords

Canada ,Denmark ,Canadians ,Canadian , ,Twitter ,Health Canada ,Novo Nordisk Canada Inc ,Novo Nordisk ,Coagulation Factor ,Product Monograph ,Christmas Disease ,Nordisk Canada ,Amy Snow ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Publishing Amp Information Services ,Children ,